Compare iShares MSCI Hong Kong ETF (EWH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $21.72 (market cap $1.15B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2× iShares MSCI Hong Kong ETF's market cap, and Recursion Pharmaceuticals Inc is more actively traded (40,478,768 versus 2,444,357). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWH | RXRX | |
|---|---|---|
Market Cap | $1.15B | $2.31B |
Volume | 2,444,357 | 40,478,768 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $6.79 |
52-Week Low | $20.66 | $2.84 |
Typical Hold Time | 61 Days | 22 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $21.58, down 0.19% with a bearish technical signal as moving averages show strong selling pressure. The ETF tracks Hong Kong's Hang Seng Index, which has faced significant volatility due to US-China tensions and Federal Reserve policy concerns. Recent institutional selling by Empowered Funds LLC (70.2% reduction in Q2 2026) reflects cautious sentiment toward Hong Kong markets.
Outlook remains challenged by geopolitical risks and Hong Kong market volatility, though oversold RSI levels suggest potential for near-term technical bounce. Key risks include continued US-China tensions and Fed policy uncertainty, while opportunities exist if Hong Kong equities stabilize. The ETF lacks fundamental metrics as it tracks an index rather than operating as a standalone company.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
